Form 8-K - Current report:
SEC Accession No. 0001193125-26-157126
Filing Date
2026-04-15
Accepted
2026-04-15 16:32:59
Documents
9
Period of Report
2026-04-09
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Document Format Files

Seq Description Document Type Size
1 8-K tcrt-20260409.htm   iXBRL 8-K 57651
  Complete submission text file 0001193125-26-157126.txt   167563

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT tcrt-20260409.xsd EX-101.SCH 27376
12 EXTRACTED XBRL INSTANCE DOCUMENT tcrt-20260409_htm.xml XML 4721
Mailing Address 501 E LAS OLAS BLVD SUITE 300 FORT LAUDERDALE FL 33301
Business Address 501 E LAS OLAS BLVD SUITE 300 FORT LAUDERDALE FL 33301 (346) 355-4099
Alaunos Therapeutics, Inc. (Filer) CIK: 0001107421 (see all company filings)

EIN.: 841475642 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-33038 | Film No.: 26864533
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)